Atezolizumab and bevacizumab in patients with advanced hepatocellular carcinoma with impaired liver function and prior systemic therapy: a real-world experience

OBJECTIVE: Evaluation of the efficacy and safety of atezolizumab/bevacizumab in a real-world HCC cohort, including patients with impaired liver function and prior systemic therapy. METHODS: Retrospective analysis of 147 HCC patients treated with atezolizumab/bevacizumab at six sites in Germany and A...

Descripción completa

Detalles Bibliográficos
Autores principales: de Castro, Tiago, Jochheim, Leonie S., Bathon, Melanie, Welland, Sabrina, Scheiner, Bernhard, Shmanko, Kateryna, Roessler, Daniel, Ben Khaled, Najib, Jeschke, Matthias, Ludwig, Johannes M., Marquardt, Jens U., Weinmann, Arndt, Pinter, Matthias, Lange, Christian M., Vogel, Arndt, Saborowski, Anna
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2022
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8891886/
https://www.ncbi.nlm.nih.gov/pubmed/35251317
http://dx.doi.org/10.1177/17588359221080298

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8891886/
https://www.ncbi.nlm.nih.gov/pubmed/35251317
http://dx.doi.org/10.1177/17588359221080298

Ejemplares similares